Four authors reply

American Journal of Epidemiology

Volumn 168, Issue 10, 2008, Pages 1213-1214

  Prentice, Ross L ^a   Chlebowski, Rowan T ^b   Rossouw, Jacques E ^c   Anderson, Garnet L ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE;

ANALYTIC METHOD; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CLINICAL TRIAL; DATA ANALYSIS; HAZARD RATIO; HORMONAL THERAPY; HUMAN; LETTER; MENOPAUSE; OBSERVATIONAL STUDY;

EID: 56449085256     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwn313     Document Type: Letter

References (5)

1. Shapiro S. Re: "Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study" [letter]. Am J Epidemiol. 2008;168(10):1213.
2. Prentice RL, Chlebowski RT, Stefanick ML, et al. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol. 2008;167(12):1407-1415.
3. Prentice RL, Chlebowski RT, Stefanick ML, et al. Estrogen plus progestin therapy and breast cancer among recently postmenopausal women. Am J Epidemiol. 2008;167(10):1207-1216.
4. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419-427.
5. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1997;350(9084):1047-1059.